Pharma channel feed

Bio­Marin strikes co­op­er­a­tion deal with ac­tivist in­vestor El­liott, sets up re­view com­mit­tee and adds board mem­bers

Last year
People

Bris­tol My­ers gets reg­u­la­to­ry clear­ance to close Mi­rati deal as FTC in­creas­es pres­sure on phar­ma M&A

Last year
Deals

Ab­b­Vie files trade se­crets suit against Ad­cen­trx and for­mer em­ploy­ee

Last year
Law

FDA to set up new Of­fice of the Chief Med­ical Of­fi­cer as part of agency reshuf­fling

Last year
FDA+

Genen­tech's food al­ler­gy med­ica­tion gets pri­or­i­ty re­view nod from the FDA

Last year
FDA+

FDA en­cour­ages col­lab­o­ra­tion be­tween mon­o­clon­al an­ti­body spon­sors to keep pace with emerg­ing Covid vari­ants

Last year
R&D
FDA+

The 2023 win­ners and losers list: Who was up and who was down in bio­phar­ma

Last year

FTC lays out road map for merg­er re­view in over­haul of decade-old an­titrust frame­work

Last year
Law

FDA ap­proves Chiesi’s gel for rare skin dis­ease af­ter ini­tial 2022 re­jec­tion for Am­ryt

Last year
FDA+

Ger­man court de­nies va­lid­i­ty of Cure­Vac patent claim in fight with BioN­Tech over Covid-19 vac­cine 

Last year
Law

How Eli Lil­ly is rolling out Zep­bound, the weight loss drug that can 'sell it­self’

Last year
Marketing

Mer­ck clinch­es pri­or­i­ty re­view for pneu­mo­coc­cal vac­cine, rais­ing stakes for Pfiz­er

Last year
FDA+

Mar­ket­ingRx roundup: Ver­tex, CRISPR get un­in­tend­ed role in SNL skit; Re­al Chem­istry and can­cer so­ci­ety de­but AI ef­fort

Last year
Marketing

FDA broad­ens au­tho­riza­tion for Ak­il­i's video game for AD­HD

Last year
FDA+

Organon adds Eli Lil­ly mi­graine meds to wom­en's health port­fo­lio in Eu­rope

Last year
Deals

Ar­cutis scores FDA ap­proval for new foam treat­ment for com­mon skin con­di­tion

Last year
FDA+

Atara Bio­ther­a­peu­tics to lay off 73 Cal­i­for­nia em­ploy­ees by the end of the year

Last year
R&D

FDA fi­nal­izes opi­oid safe­ty la­bel­ing changes

Last year
FDA+

Bris­tol My­ers cuts PhI­II PD-1/LAG-3 tri­al in col­orec­tal can­cer short af­ter drug com­bo fails analy­sis

Last year
R&D

Mer­ck­'s Welireg wins la­bel ex­pan­sion in kid­ney can­cer de­spite miss­ing sur­vival da­ta

Last year
FDA+

FDA con­verts ac­cel­er­at­ed to full ap­proval for Pad­cev-Keytru­da com­bo in blad­der can­cer

Last year
FDA+

Ab­b­Vie winds down five-year, $350M phil­an­thropy pledge

Last year
Marketing

Eu­rope lines up first CRISPR ther­a­py ap­proval

Last year
FDA+

PhRMA and BIO say Biden’s march-in pro­pos­al cre­ates un­cer­tain­ty in in­dus­try

Last year
First page Previous page 79808182838485 Next page Last page
A service from the Financial Times